SHR-A1921 with or without carboplatin for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new targeted drug, SHR-A1921, given alone or with chemotherapy (carboplatin) for people with ovarian cancer that has come back or spread. It aims to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has spread or come back.
- You need to be able to provide a sample of your tumor tissue (either from a past biopsy or a new one).
- You should have at least one tumor that can be measured on a scan.
- You must be feeling well enough to take care of yourself (ECOG score 0-1) and have a life expectancy of at least 12 weeks.
- You cannot have uncontrolled fluid buildup in your chest, belly, or around the heart that causes symptoms.
- You cannot have had certain prior treatments, including drugs called TOP1 inhibitors or ADCs that use them.
- You cannot have a history of lung inflammation (interstitial lung disease or pneumonitis) that needed steroids, or any current active lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new drug, SHR-A1811, for ovarian cancer that came back after responding well to platinum chemo. It is for people with BRCA mutations or HRD positive status who have already tried a PARP inhibitor.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
This trial tests a new targeted drug (SHR-A1811) against standard chemotherapy for ovarian cancer that no longer responds to platinum drugs. It's for people whose tumors have a specific protein called HER2, and who have had limited prior treatments after platinum resistance.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.